Date
|
Name
|
Institution
|
Seminar
|
| Nov. 1, 2000 |
Vanessa Hirsch, D.V.M., Sc.D. |
Laboratory of Molecular Microbiology, NIAID |
Modified vaccinia virus ankara (MVA) as a potential live vaccine vector for AIDS |
| July 26, 2000 |
James Earl King Hildreth, Ph.D., M.D. |
John Hopkins University School of Medicine |
Role of ADCC in protection against HIV infection |
| June 26, 2000 |
Heinrich G. Göttlinger, M.D. |
Dana Farber Cancer Institute |
A general role for ubiquitin ligase in recruitment in retrovirus release |
| June 19, 2000 |
Hildegund C.J. Ertl, M.D. |
The Wistar Institute, Philadelphia, PA |
Vaccine induced responses to viruses and cancer |
| June 8, 2000 |
Richard T. Wyatt, Ph.D. |
Dana-Farber Cancer Institute |
HIV-1 gp 120 structural analysis and mechanisms of immune evasion |
| June 5, 2000 |
Carol D. Weiss, M.D., Ph.D. |
Center for Biologics, FDA |
Lessons from HIV entry |
| May 25, 2000 |
Ligia A. Pinto, Ph.D. |
Experimental Immunology Branch, NIH |
Novel approaches for immunologic control of HIV infection: Implications for vaccine design |
| May 10, 2000 |
Peter D. Kwong, Ph.D. |
Columbia University |
The HIV gp120 envelope glycoprotein: structure, function and vaccine design |
| Apr. 28, 2000 |
Richard Koup, M.D. |
The University of Texas Southwestern Medical Center |
Measuring immune responses and immune reconstitution in HIV infected patients |
| Apr. 25, 2000 |
Jeff Frelinger, Ph.D. |
University of North Carolina |
An immunologist looks at HIV vaccines |
| Apr. 13, 2000 |
Nina Bhardwaj, M.D., Ph.D. |
Rockefeller University |
Dendritic cells, apoptosis, and immunity |
| Mar. 28, 2000 |
Daniel Douek, Ph.D. |
University of Texas Southwestern Medical School |
Immune reconstitution - The thymus and factors that affect its function |
| Mar. 24, 2000 |
Ira Berkower, M.D., Ph.D. |
Center for Biologics, FDA |
Novel vaccine constructs for enhanced immunogenicity |
| Mar. 17, 2000 |
Jonthan Yewdell, M.D., Ph.D. |
Laboratory of Viral Diseases NIAID |
Protein folding, unfolding and QC meet the MHC class I antigen processing pathway |
| Mar. 16, 2000 |
Jack Bennink, Ph.D. |
Laboratory of Viral Diseases, NIAID |
Immunodominance in anti-viral MHC class I restricted T-cell responses |
| Mar. 13, 2000 |
George Gao, Ph.D. |
Harvard University |
Coordination of alpha/beta T cell receptor and co-receptor CD8 in T cell recognition |
| Mar. 3, 2000 |
Guangxia Gao, Ph.D. |
Columbia University |
Genetic analysis of viral and cellular functions of retroviral infection |
| Mar. 2, 2000 |
Robert Donahue, D.V.M. |
National Heart, Lung and Blood Institute |
Non-human primate hematopoietic cell gene therapy |
| Feb. 28, 2000 |
Igor Belyakov, M.D., Ph.D. |
Metabolism Branch, BCI, NIH |
A rational basis for mucosal vaccination against HIV infection |
| Feb. 17, 2000 |
Melisssa Pope, Ph.D. |
Rockefeller University |
Presentation of simian immunodeficiency virus by dendritic cells: immune activation versus virus replication |
| Feb. 11, 2000 |
Louis Alexander, Ph.D. |
Harvard Medical School |
Nef functions that contribute to HIV-1 and SIV pathogenesis |
| Jan. 21, 2000 |
Douglas Nixon, M.D., Ph.D. |
Aaron Diamond AIDS Research Center |
HIV specific CTL and protection against infection with HIV |
| Jan. 19, 2000 |
Robert Seder, M.D. |
Laboratory of Clinical Investigation, NIAID |
Vaccine requirements for sustained Th 1 immunity in vivo |
| Jan. 14, 2000 |
Dennis Klinman, M.D., Ph.D. |
Center for Biologics Evaluation and Research, FDA |
Immunotherapeutic Potential of CpG-containing DNA |